Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company,
today announced that Gerald T. Proehl, president and chief executive
officer, will make a presentation at the BMO Capital Markets 9th
Annual Focus on Healthcare Conference on Wednesday, August 5, 2009 at
11:15 a.m. Eastern time (8:15 a.m. Pacific time) at the Millennium
Broadway Hotel in New York City.
A webcast of the presentation will be available during the event at www.santarus.com
and will be archived and available on the Web site for 14 days.
About Santarus
Santarus, Inc. is a specialty biopharmaceutical company focused on
acquiring, developing and commercializing proprietary products that
address the needs of patients treated by gastroenterologists and other
targeted physicians. The company’s current commercial efforts are
focused on ZEGERID® (omeprazole/sodium bicarbonate) Capsules
and Powder for Oral Suspension, which are indicated for the treatment of
certain upper GI diseases and disorders, and on GLUMETZA®
(metformin hydrochloride extended release tablets), which are indicated
as an adjunct to diet and exercise to improve glycemic control in adults
with type 2 diabetes. Santarus is also developing two late-stage lower
GI product candidates, budesonide MMX® and rifamycin SV MMX®,
for the U.S. market. Budesonide MMX is being investigated in two
multicenter Phase III clinical trials for the induction of remission of
mild or moderate active ulcerative colitis. Rifamycin SV MMX has been
investigated in a Phase II clinical program in traveler’s diarrhea. More
information about Santarus is available on the company’s Web site at www.santarus.com.
Santarus cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements. The inclusion of forward-looking statements should
not be regarded as a representation by Santarus that any of its plans
will be achieved. Actual results may differ materially from those set
forth in this release due to the risks and uncertainties inherent in
Santarus’ business, including, without limitation: difficulties or
delays in development, testing, manufacturing and marketing of, and
obtaining and maintaining regulatory approvals for, Santarus’ products;
and other risks detailed in Santarus’ prior press releases as well as in
public periodic filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Santarus undertakes no obligation to revise or
update this news release to reflect events or circumstances after the
date hereof. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation Reform
Act of 1995.
Santarus® and ZEGERID®
are registered trademarks of Santarus, Inc. GLUMETZA® is
a registered trademark of Biovail Laboratories International S.r.l.
licensed exclusively in the United States to Depomed, Inc. MMX®
is a registered trademark of Cosmo Technologies Limited.
Company Contact:
Santarus, Inc.
Martha L. Hough, VP
Finance & Investor Relations
858-314-5824
Debra P.
Crawford, Chief Financial Officer
858-314-5708
or
Investor
Contact:
Lippert/Heilshorn & Associates, Inc.
Jody
Cain / Bruce Voss, 310-691-7100
jcain@lhai.com
bvoss@lhai.com
